B-and T-lymphocyte attenuator targeting protects against the acute phase of graft versus host reaction by inhibiting donor anti-host cytotoxicity

Transplantation

Volumn 92, Issue 10, 2011, Pages 1085-1093

  Del Rio, Maria Luisa ^a   Kurtz, Josef ^b,c   Perez Martinez, Claudia ^a   Ghosh, Arnab ^d   Perez Simon, José Antonio ^e   Rodriguez Barbosa, Jose Ignacio ^a  

^a UNIVERSITY OF LEÓN   (Spain)

^b EMMANUEL COLLEGE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Alloreactivity; BTLA; Cosignaling; GvHR; HVEM

Indexed keywords

B AND T LYMPHOCYTE ATTENUATOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4G12B; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SINGLE DRUG DOSE; THYMUS;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; CYTOTOXICITY, IMMUNOLOGIC; GRAFT REJECTION; GRAFT VS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES, CYTOTOXIC;

EID: 80855123469     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182339d4a     Document Type: Article

References (37)

1. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23: 515.
2. Greenwald RJ, Latchman YE, Sharpe AH. Negative co-receptors on lymphocytes. Curr Opin Immunol 2002; 14: 391.
3. Murphy TL, Murphy KM. Slow down and survive: Enigmatic Immunoregulation by BTLA and HVEM. Annu Rev Immunol 2010; 28: 389.
4. Gavrieli M, Watanabe N, Loftin SK, et al. Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. Biochem Biophys Res Commun 2003; 312: 1236.
5. Vendel AC, Calemine-Fenaux J, Izrael-Tomasevic A, et al. B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK. J Immunol 2009; 182: 1509.
6. Chemnitz JM, Lanfranco AR, Braunstein I, et al. B and T lymphocyte attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs. J Immunol 2006; 176: 6603.
7. Watanabe N, Gavrieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003; 4: 670.
8. Hurchla MA, Sedy JR, Gavrieli M, et al. B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly induced in anergic CD4+T cells. J Immunol 2005; 174: 3377.
9. Han P, Goularte OD, Rufner K, et al. An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. J Immunol 2004; 172: 5931.
10. Del Rio ML, Kaye J, Rodriguez-Barbosa JI. Detection of protein on BTLAlow cells and in vivo antibody-mediated down-modulation of BTLA on lymphoid and myeloid cells of C57BL/6 and BALB/c BTLA allelic variants. Immunobiology 2010; 215: 570.
11. Cheung TC, Steinberg MW, Oborne LM, et al. Unconventional ligand activation of herpesvirus entry mediator signals cell survival. Proc Natl Acad Sci USA 2009; 106: 6244.
12. Cheung TC, Oborne LM, Steinberg MW, et al. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment. J Immunol 2009; 183: 7286.
13. Krieg C, Boyman O, Fu YX, et al. B and T lymphocyte attenuator regulates CD8-T cell-intrinsic homeostasis and memory cell generation. Nat Immunol 2007; 8: 162.
14. Oya Y, Watanabe N, Owada T, et al. Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheum 2008; 58: 2498.
15. Tao R, Wang L, Han R, et al. Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts. J Immunol 2005; 175: 5774.
16. Hurchla MA, Sedy JR, Murphy KM. Unexpected role of B and T lymphocyte attenuator in sustaining cell survival during chronic allostimulation. J Immunol 2007; 178: 6073.
17. Sakoda Y, Park JJ, Zhao Y, et al. Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway. Blood 2011; 117: 2506.
18. Albring JC, Sandau MM, Rapaport AS, et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. J Exp Med 2010; 207: 2551.
19. Tschetter JR, Mozes E, Shearer GM. Progression from acute to chronic disease in a murine parent-into-F1 model of graft-versus-host disease. J Immunol 2000; 165: 5987.
20. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007; 7: 340.
21. Puliaev RA, Puliaeva IA, Ryan AE, et al. The parent-into-F1 model of graft-vs-host disease as a model of in vivo T cell function and immunomodulation. Curr Med Chem Immunol Endocr Metab Agents 2005; 5: 575.
22. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27: 195.
23. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405.
24. Gonzalez LC, Loyet KM, Calemine-Fenaux J, et al. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci USA 2005; 102: 1116.
25. Sedy JR, Gavrieli M, Potter KG, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005; 6: 90.
26. Cai G, Anumanthan A, Brown JA, et al. CD160 inhibits activation of human CD4-T cells through interaction with herpesvirus entry mediator. Nat Immunol 2008; 9: 176.
27. Kubota T, Niwa R, Satoh M, et al. Engineered therapeutic antibodies with improved effector functions. Cancer Sci 2009; 100: 1566.
28. Brüggemann M, Teale C, Clark M, et al. A matched set of rat/mouse chimeric antibodies. Identification and biological properties of rat H chain constant regions mu, gamma 1, gamma 2a, gamma 2b, gamma 2c, epsilon, and alpha J Immunol 1989; 142: 3145.
29. Del Rio ML, Lucas CL, Buhler L, et al. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. J Leukoc Biol 2010; 87: 223.
30. Truong W, Plester JC, Hancock WW, et al. Negative and positive cosignaling with anti-BTLA (PJ196) and CTLA4Ig prolongs islet allograft survival. Transplantation 2007; 84: 1368.
31. Benhamou PY. Immunomodulation with CTLA4-Ig in islet transplantation. Transplantation 2002; 73: S40.
32. Truong W, Plester JC, HancockWW,et al. Combined coinhibitory and costimulatory modulation with anti-BTLA and CTLA4Ig facilitates tolerance in murine islet allografts. Am J Transplant 2007; 7: 2663.
33. Oehen S, Brduscha-Riem K, Oxenius A, et al. A simple method for evaluating the rejection of grafted spleen cells by flow cytometry and tracing adoptively transferred cells by light microscopy. J Immunol Methods 1997; 207: 33.
34. Brehm MA, Daniels KA, Ortaldo JR, et al. Rapid conversion of effector mechanisms fromNKto T cells during virus-induced lysis of allogeneic implants in vivo. J Immunol 2005; 174: 6663.
35. Del Rio ML, Cote-Sierra J, Rodriguez-Barbosa JI. Flt3L-mobilized dendritic cells bearing H2-K(bm1) apoptotic cells do not induce crosstolerance to CD8(+) T cells across a class I MHC mismatched barrier. Transpl Int 2011; 24: 501.
36. Del Rio ML, Rodriguez-Barbosa JI, Kremmer E, et al. CD103-and CD103+bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+and CD8+T cells. J Immunol 2007; 178: 6861.
37. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281: 65.